These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 30296624

  • 1. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
    Tremblay G, Chounta V, Piercy J, Holbrook T, Garib SA, Bukin EK, Punekar YS.
    Value Health Reg Issues; 2018 Sep; 16():74-80. PubMed ID: 30296624
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
    Butler K, Anderson SJ, Hayward O, Jacob I, Punekar YS, Evitt LA, Oglesby A.
    J Manag Care Spec Pharm; 2021 Jul; 27(7):891-903. PubMed ID: 34185564
    [Abstract] [Full Text] [Related]

  • 6. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P, Mills A, Carpio F, Hsu R, DeJesus E, Pierone G, Henegar C, Fusco J, Fusco G, Wohlfeiler M.
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [Abstract] [Full Text] [Related]

  • 7. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP.
    Clin Infect Dis; 2016 Mar 15; 62(6):784-91. PubMed ID: 26658053
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG, Chamorro-de-Vega E, Ortega-Navarro C, Alonso R, Herranz-Alonso A, Sanjurjo-Saez M.
    Ann Pharmacother; 2020 Jul 15; 54(7):633-643. PubMed ID: 31910643
    [Abstract] [Full Text] [Related]

  • 9. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
    Raffi F, Rachlis A, Brinson C, Arasteh K, Górgolas M, Brennan C, Pappa K, Almond S, Granier C, Nichols WG, Cuffe RL, Eron J, Walmsley S.
    AIDS; 2015 Jan 14; 29(2):167-74. PubMed ID: 25387312
    [Abstract] [Full Text] [Related]

  • 10. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators.
    N Engl J Med; 2013 Nov 07; 369(19):1807-18. PubMed ID: 24195548
    [Abstract] [Full Text] [Related]

  • 11. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
    Trottier B, Lake JE, Logue K, Brinson C, Santiago L, Brennan C, Koteff JA, Wynne B, Hopking J, Granier C, Aboud M.
    Antivir Ther; 2017 Nov 07; 22(4):295-305. PubMed ID: 28401876
    [Abstract] [Full Text] [Related]

  • 12. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
    Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, Stephens J, Nichols G.
    PLoS One; 2014 Nov 07; 9(9):e105653. PubMed ID: 25188312
    [Abstract] [Full Text] [Related]

  • 13. Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France.
    Pialoux G, Marcelin AG, Despiégel N, Espinas C, Cawston H, Finkielsztejn L, Laurisse A, Aubin C.
    PLoS One; 2015 Nov 07; 10(12):e0145885. PubMed ID: 26714188
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
    Hidalgo-Tenorio C, Cortés LL, Gutiérrez A, Santos J, Omar M, Gálvez C, Sequera S, Jesús SE, Téllez F, Fernández E, García C, Pasquau J.
    Medicine (Baltimore); 2019 Aug 07; 98(32):e16813. PubMed ID: 31393412
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
    Hocqueloux L, Raffi F, Prazuck T, Bernard L, Sunder S, Esnault JL, Rey D, Le Moal G, Roncato-Saberan M, André M, Billaud E, Valéry A, Avettand-Fènoël V, Parienti JJ, Allavena C, MONCAY study group.
    Clin Infect Dis; 2019 Oct 15; 69(9):1498-1505. PubMed ID: 30601976
    [Abstract] [Full Text] [Related]

  • 18. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
    Evitt LA, Nanji S, Grove RA, Okoli C, van Wyk J, Snedecor SJ.
    AIDS Res Ther; 2023 Mar 22; 20(1):17. PubMed ID: 36949442
    [Abstract] [Full Text] [Related]

  • 19. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.
    Colson A, Chastek B, Gruber J, Majethia S, Zachry W, Mezzio D, Rock M, Anderson A, Cohen JP.
    J Manag Care Spec Pharm; 2024 Aug 22; 30(8):817-824. PubMed ID: 39088337
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K, Halfpenny NJA, Snedecor SJ, Punekar YS.
    BMC Infect Dis; 2021 Feb 26; 21(1):222. PubMed ID: 33637050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.